The deal includes a licensing fee, milestone payments and royalties based on product sales. The company said that the pharmaceutical partner is dedicated to dermatology with an extensive
The pharmaceutical partner is dedicated to dermatology with an extensive product portfolio available in 80 countries. The long-term license deal, which provides for upfront and milestone payments and
Combination of Empiriko’s chemosynthetic livers and Interchim’s innovative instrumentation and expertise in the field of liquid chromatography allows pharmaceutical scientists to predict metabolism patterns, pathways and profiles, while
The company is replacing a mix of highly customized solutions built on an outdated legacy platform with Veeva Systems’ suite of applications, spanning from clinical to commercial. The
In June 2013, the three parties have collaborated on to build the new center to address increasing demand from pharmaceutical and other Iife science companies for comprehensive imaging
Primary endpoint of the trial is reduction in the Ulcerative Colitis Disease Activity Index (UCDAI) at six weeks, while secondary endpoints include endoscopic remission, reduction in UCDAI at
Phosgene, which is classified as a toxic industrial chemical, is currently used to make chemicals and pesticides. At room temperature Phosgene is a poisonous gas and poses a
VS-4718 is an oral compound that is designed to target cancer stem cells via the potent inhibition of focal adhesion kinase (FAK). The company said that cancer stem
MONOVISC is a single injection supplement to synovial fluid of the osteoarthritic joint, indicated to treat pain and improve joint mobility in these patients who have failed to
Under the deal, PMV Pharma will have a non-exclusive license to use Chiromics’ chemical compound library and a screening collaboration to discover and optimize new small molecules against
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.